HOME >> BIOLOGY >> NEWS
Experimental drug shown to block mutant protein causing blood disease

BOSTON--Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

The researchers also tested the drug, PKC412, in a patient with the hard-to-treat disease, called Myeloproliferative Disease (MPD), and saw her symptoms improve.

PKC412, like the spotlight drug Gleevec, is a highly specific "targeted" drug that disables a switch in cancer cells that has become jammed in the "on" position because of a genetic mutation. The glitch allows a continuous stream of signals to prod blood cells into an uncontrolled frenzy of division and growth. The overproduction of white blood cells in MPD damages organs and generally turns into an acute leukemia that can be fatal.

The report appears in this week's Online Early Edition of the Proceedings of the National Academy of Sciences. Jing Chen, PhD, of Brigham and Women's, and Daniel J. DeAngelo, MD, PhD, of Dana-Farber, are the paper's co-first authors. D. Gary Gilliland, MD, PhD, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital, and Richard M. Stone, MD, of Dana-Farber are the senior authors. Other authors are from Dana-Farber, Brigham and Women's, Harvard Medical School, Emory University, and Novartis Pharma AG.

"The study shows the potential utility of drugs that block mutant tyrosine kinases, and that these drugs are opening more doors to treating cancers," explains Stone.

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been discovered to be major culprits in many forms of cancer. Because inhibitor drugs strike the abnormal kinases in cancer cells without harming normal tissue, they are associated with fewer side effects than standard cancer drugs.

In the study, mice with MP
'"/>

Contact: Bill Schaller or Richard Saltus
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
21-Sep-2004


Page: 1 2

Related biology news :

1. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
2. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... ... 2019 , ... Noblis, Inc., a leading provider of science, ... and Methods for SNP Analysis and Genome Sequencing.” Noblis’ new system and methods ... bioinformatic analyses, including SNP calling, metagenomic analysis, and conserved and signature sequence detection. ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... other services to clinical trial sponsors, has entered into a multi-year agreement with ... enable Quartesian, a member of Medrio’s Certified Partner Program, to leverage the full ...
(Date:4/16/2019)... NEW YORK (PRWEB) , ... April 16, 2019 ... ... the Top 50 Healthcare Technology CEOs of 2019 . An extensive process ... the fields of medical devices, biotech, healthcare analytics, healthcare software and other related ...
Breaking Biology News(10 mins):
(Date:4/12/2019)... ... April 12, 2019 , ... ... neurotechnology and will educate about innovative tools and devices being used to enhance ... for more information. , This segment of Advancements will focus on Sound for ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/8/2019)... SOUTH JORDAN, Utah and BOSTON (PRWEB) , ... ... ... leader in delivering cloud-based enterprise-class unified communications and collaboration solutions, announced today the ... provides integration to an unprecedented range of business and contact-orientated applications while ...
(Date:4/4/2019)... ... April 02, 2019 , ... ... would be releasing it’s latest field-ready solution for performing PCR, RT-PCR, qPCR, and ... Franklin™ pays homage to Rosland Franklin, an English chemist and X-ray crystallographer who ...
Breaking Biology Technology:
Cached News: